Effect of prior chemotherapy regimens on the efficacy of endocrine therapy within a German cohort of the TEAM trial

Purpose Prior chemotherapy may affect the efficacy of endocrine therapy. Methods The tamoxifen exemestane adjuvant multinational (TEAM) trial compared 5 years of adjuvant exemestane with the sequence of tamoxifen followed by exemestane in postmenopausal women with hormone-receptor-positive breast ca...

Full description

Saved in:
Bibliographic Details
Published inJournal of cancer research and clinical oncology Vol. 140; no. 1; pp. 117 - 126
Main Authors Bossart, Michaela, Hadji, Peyman, Klar, Maximilian, Kieback, Dirk G., Hasenburg, Annette
Format Journal Article
LanguageEnglish
Published Berlin/Heidelberg Springer Berlin Heidelberg 2014
Springer Nature B.V
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Purpose Prior chemotherapy may affect the efficacy of endocrine therapy. Methods The tamoxifen exemestane adjuvant multinational (TEAM) trial compared 5 years of adjuvant exemestane with the sequence of tamoxifen followed by exemestane in postmenopausal women with hormone-receptor-positive breast cancer. A total of 1,502 patients were enrolled in Germany (739 received tamoxifen followed by exemestan and 610 exemestan alone). A retrospective analysis of the German cohort of TEAM was conducted to determine whether prior chemotherapy affected clinical outcome of endocrine therapy. Results Overall survival, disease-free survival and distant recurrence were similar between patients who received sequential therapy and those who received exemestane monotherapy, irrespective of prior chemotherapy. Overall survival was not significantly different between patients who had received prior chemotherapy and those who had not ( P  = 0.2836). Disease-free survival and distant recurrence were significantly better in patients who had not received prior chemotherapy versus those who had ( P  = 0.0308 and P  = 0.0001). In patients receiving sequential therapy, there were no significant differences in overall survival according to prior chemotherapy use ( P  = 0.1812). However, disease-free survival and distant recurrence were significantly different dependent on prior chemotherapy ( P  = 0.0143 and P  = 0.0053). Conclusion In conclusion, there was no difference in overall survival between breast cancer patients who did receive prior chemotherapy before endocrine therapy and those who had not. Patients who had not received prior chemotherapy had significantly improved disease-free survival and less distant recurrence versus those who had received chemotherapy.
AbstractList Prior chemotherapy may affect the efficacy of endocrine therapy. The tamoxifen exemestane adjuvant multinational (TEAM) trial compared 5 years of adjuvant exemestane with the sequence of tamoxifen followed by exemestane in postmenopausal women with hormone-receptor-positive breast cancer. A total of 1,502 patients were enrolled in Germany (739 received tamoxifen followed by exemestan and 610 exemestan alone). A retrospective analysis of the German cohort of TEAM was conducted to determine whether prior chemotherapy affected clinical outcome of endocrine therapy. Overall survival, disease-free survival and distant recurrence were similar between patients who received sequential therapy and those who received exemestane monotherapy, irrespective of prior chemotherapy. Overall survival was not significantly different between patients who had received prior chemotherapy and those who had not (P = 0.2836). Disease-free survival and distant recurrence were significantly better in patients who had not received prior chemotherapy versus those who had (P = 0.0308 and P = 0.0001). In patients receiving sequential therapy, there were no significant differences in overall survival according to prior chemotherapy use (P = 0.1812). However, disease-free survival and distant recurrence were significantly different dependent on prior chemotherapy (P = 0.0143 and P = 0.0053). In conclusion, there was no difference in overall survival between breast cancer patients who did receive prior chemotherapy before endocrine therapy and those who had not. Patients who had not received prior chemotherapy had significantly improved disease-free survival and less distant recurrence versus those who had received chemotherapy.
Purpose Prior chemotherapy may affect the efficacy of endocrine therapy. Methods The tamoxifen exemestane adjuvant multinational (TEAM) trial compared 5 years of adjuvant exemestane with the sequence of tamoxifen followed by exemestane in postmenopausal women with hormone-receptor-positive breast cancer. A total of 1,502 patients were enrolled in Germany (739 received tamoxifen followed by exemestan and 610 exemestan alone). A retrospective analysis of the German cohort of TEAM was conducted to determine whether prior chemotherapy affected clinical outcome of endocrine therapy. Results Overall survival, disease-free survival and distant recurrence were similar between patients who received sequential therapy and those who received exemestane monotherapy, irrespective of prior chemotherapy. Overall survival was not significantly different between patients who had received prior chemotherapy and those who had not ( P  = 0.2836). Disease-free survival and distant recurrence were significantly better in patients who had not received prior chemotherapy versus those who had ( P  = 0.0308 and P  = 0.0001). In patients receiving sequential therapy, there were no significant differences in overall survival according to prior chemotherapy use ( P  = 0.1812). However, disease-free survival and distant recurrence were significantly different dependent on prior chemotherapy ( P  = 0.0143 and P  = 0.0053). Conclusion In conclusion, there was no difference in overall survival between breast cancer patients who did receive prior chemotherapy before endocrine therapy and those who had not. Patients who had not received prior chemotherapy had significantly improved disease-free survival and less distant recurrence versus those who had received chemotherapy.
Prior chemotherapy may affect the efficacy of endocrine therapy. The tamoxifen exemestane adjuvant multinational (TEAM) trial compared 5 years of adjuvant exemestane with the sequence of tamoxifen followed by exemestane in postmenopausal women with hormone-receptor-positive breast cancer. A total of 1,502 patients were enrolled in Germany (739 received tamoxifen followed by exemestan and 610 exemestan alone). A retrospective analysis of the German cohort of TEAM was conducted to determine whether prior chemotherapy affected clinical outcome of endocrine therapy. Overall survival, disease-free survival and distant recurrence were similar between patients who received sequential therapy and those who received exemestane monotherapy, irrespective of prior chemotherapy. Overall survival was not significantly different between patients who had received prior chemotherapy and those who had not (P = 0.2836). Disease-free survival and distant recurrence were significantly better in patients who had not received prior chemotherapy versus those who had (P = 0.0308 and P = 0.0001). In patients receiving sequential therapy, there were no significant differences in overall survival according to prior chemotherapy use (P = 0.1812). However, disease-free survival and distant recurrence were significantly different dependent on prior chemotherapy (P = 0.0143 and P = 0.0053). In conclusion, there was no difference in overall survival between breast cancer patients who did receive prior chemotherapy before endocrine therapy and those who had not. Patients who had not received prior chemotherapy had significantly improved disease-free survival and less distant recurrence versus those who had received chemotherapy.[PUBLICATION ABSTRACT]
PURPOSEPrior chemotherapy may affect the efficacy of endocrine therapy. METHODSThe tamoxifen exemestane adjuvant multinational (TEAM) trial compared 5 years of adjuvant exemestane with the sequence of tamoxifen followed by exemestane in postmenopausal women with hormone-receptor-positive breast cancer. A total of 1,502 patients were enrolled in Germany (739 received tamoxifen followed by exemestan and 610 exemestan alone). A retrospective analysis of the German cohort of TEAM was conducted to determine whether prior chemotherapy affected clinical outcome of endocrine therapy. RESULTSOverall survival, disease-free survival and distant recurrence were similar between patients who received sequential therapy and those who received exemestane monotherapy, irrespective of prior chemotherapy. Overall survival was not significantly different between patients who had received prior chemotherapy and those who had not (P = 0.2836). Disease-free survival and distant recurrence were significantly better in patients who had not received prior chemotherapy versus those who had (P = 0.0308 and P = 0.0001). In patients receiving sequential therapy, there were no significant differences in overall survival according to prior chemotherapy use (P = 0.1812). However, disease-free survival and distant recurrence were significantly different dependent on prior chemotherapy (P = 0.0143 and P = 0.0053). CONCLUSIONIn conclusion, there was no difference in overall survival between breast cancer patients who did receive prior chemotherapy before endocrine therapy and those who had not. Patients who had not received prior chemotherapy had significantly improved disease-free survival and less distant recurrence versus those who had received chemotherapy.
Author Klar, Maximilian
Hadji, Peyman
Hasenburg, Annette
Kieback, Dirk G.
Bossart, Michaela
Author_xml – sequence: 1
  givenname: Michaela
  surname: Bossart
  fullname: Bossart, Michaela
  email: Michaela.Bossart@uniklinik-freiburg.de
  organization: University Hospital Freiburg
– sequence: 2
  givenname: Peyman
  surname: Hadji
  fullname: Hadji, Peyman
  organization: Philipps-University of Marburg
– sequence: 3
  givenname: Maximilian
  surname: Klar
  fullname: Klar, Maximilian
  organization: University Hospital Freiburg
– sequence: 4
  givenname: Dirk G.
  surname: Kieback
  fullname: Kieback, Dirk G.
  organization: Paracelsus Klinik
– sequence: 5
  givenname: Annette
  surname: Hasenburg
  fullname: Hasenburg, Annette
  organization: University Hospital Freiburg
BackLink https://www.ncbi.nlm.nih.gov/pubmed/24271056$$D View this record in MEDLINE/PubMed
BookMark eNp1kcFqGzEQhkVJqR23D9BLEOTSy6YaabXKHk1w0oJLL-lZaKVRvMYrudKa4LePtk5CKOQ0aPTNN0L_OTkLMSAhX4FdAWPqe2asFrxiICqQEqr2A5nD1AEh5BmZM1BQSQ7NjJznvGXlLBX_RGa85gqYbOYkr7xHO9Lo6T71MVG7wSGOG0xmf6QJH_oBQ6Yx0NKj6H1vjT1OOAYXbeoD0hf6sR83faCG3mEaTKA2bmL6p55m71fLX3RMvdl9Jh-92WX88lwX5M_t6v7mR7X-fffzZrmurOD1WDVegvDX1tetANsY5ZXtGOuU6riETjhUtnEchXEWHCsAemsa6cCBdV0rFuTbybtP8e8B86iHPlvc7UzAeMga6pYp2So-oZf_odt4SKG8rlBKNK0UpSwInCibYs4JvS5_Nph01MD0lIg-JaJLInpKRE_mi2fzoRvQvU68RFAAfgJyuQoPmN6sftf6BFIYmJg
Cites_doi 10.1093/annonc/mdp322
10.1016/S0140-6736(05)74803-0
10.1016/S0140-6736(10)62312-4
10.1016/S0140-6736(05)66544-0
10.1016/S0140-6736(07)60200-1
10.1093/annonc/mdq159
10.1056/NEJMoa0810818
10.1002/cncr.22042
10.1056/NEJMoa052258
10.1016/S0140-6736(02)09088-8
ContentType Journal Article
Copyright Springer-Verlag Berlin Heidelberg 2013
Springer-Verlag Berlin Heidelberg 2014
Copyright_xml – notice: Springer-Verlag Berlin Heidelberg 2013
– notice: Springer-Verlag Berlin Heidelberg 2014
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
3V.
7TO
7X7
7XB
88E
8AO
8C1
8FI
8FJ
8FK
8G5
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
GUQSH
H94
K9.
M0S
M1P
M2O
MBDVC
PQEST
PQQKQ
PQUKI
PRINS
Q9U
7X8
DOI 10.1007/s00432-013-1551-9
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
ProQuest Central (Corporate)
Oncogenes and Growth Factors Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Public Health Database (Proquest)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
Research Library (Alumni Edition)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
Research Library Prep
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
Medical Database
ProQuest research library
Research Library (Corporate)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Research Library Prep
ProQuest Central Student
Oncogenes and Growth Factors Abstracts
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
Research Library (Alumni Edition)
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
AIDS and Cancer Research Abstracts
ProQuest Research Library
ProQuest Medical Library (Alumni)
ProQuest Public Health
ProQuest Central Basic
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE

Research Library Prep
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1432-1335
EndPage 126
ExternalDocumentID 3171685251
10_1007_s00432_013_1551_9
24271056
Genre Clinical Trial, Phase III
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations Germany
GeographicLocations_xml – name: Germany
GroupedDBID ---
-53
-5E
-5G
-BR
-EM
-Y2
-~C
-~X
.55
.86
.GJ
.VR
06C
06D
0R~
0VY
199
1N0
1SB
2.D
203
28-
29K
29~
2J2
2JN
2JY
2KG
2KM
2LR
2P1
2VQ
2~H
30V
36B
3O-
3V.
4.4
406
408
409
40D
40E
53G
5QI
5RE
5VS
67Z
6NX
78A
7X7
88E
8AO
8C1
8FI
8FJ
8G5
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AABYN
AAFGU
AAHNG
AAIAL
AAJKR
AAKSU
AANXM
AANZL
AARHV
AARTL
AATNV
AATVU
AAUYE
AAWCG
AAYFA
AAYIU
AAYOK
AAYQN
AAYTO
ABBBX
ABBXA
ABDZT
ABECU
ABFGW
ABFTV
ABHLI
ABHQN
ABIPD
ABJNI
ABJOX
ABKAS
ABKCH
ABKTR
ABLJU
ABMNI
ABMQK
ABNWP
ABPLI
ABPTK
ABSXP
ABTEG
ABTKH
ABTMW
ABULA
ABUWG
ABWNU
ABXPI
ACBMV
ACBRV
ACBXY
ACBYP
ACGFS
ACHSB
ACHVE
ACHXU
ACIGE
ACIPQ
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPRK
ACTTH
ACUDM
ACVWB
ACWMK
ADBBV
ADHHG
ADHIR
ADINQ
ADKNI
ADKPE
ADMDM
ADOXG
ADRFC
ADTPH
ADURQ
ADYFF
ADZKW
AEBTG
AEEQQ
AEFIE
AEFTE
AEGAL
AEGNC
AEJHL
AEJRE
AEKMD
AENEX
AEOHA
AEPYU
AEQTP
AESKC
AESTI
AETLH
AEVLU
AEVTX
AEXYK
AFAFS
AFEXP
AFFNX
AFKRA
AFLOW
AFNRJ
AFQWF
AFWTZ
AFZKB
AGAYW
AGDGC
AGGBP
AGGDS
AGJBK
AGKHE
AGMZJ
AGQMX
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHKAY
AHMBA
AHSBF
AHYZX
AIAKS
AIIXL
AILAN
AIMYW
AITGF
AJBLW
AJDOV
AJRNO
AJZVZ
AKMHD
AKQUC
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMXSW
AMYLF
AMYQR
AOCGG
ARMRJ
ASPBG
AVWKF
AXYYD
AZFZN
AZQEC
B-.
BA0
BBWZM
BDATZ
BENPR
BGNMA
BPHCQ
BVXVI
CAG
CCPQU
COF
CS3
CSCUP
D-I
DDRTE
DL5
DNIVK
DPUIP
DU5
DWQXO
EBD
EBLON
EBS
EIOEI
EJD
EMB
EMOBN
EN4
ESBYG
F5P
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
FYUFA
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNUQQ
GNWQR
GQ6
GQ7
GQ8
GRRUI
GUQSH
GXS
HF~
HG5
HG6
HMCUK
HMJXF
HQYDN
HRMNR
HVGLF
HZ~
I09
IHE
IJ-
IKXTQ
IMOTQ
ITM
IWAJR
IXC
IZIGR
IZQ
I~X
I~Z
J-C
J0Z
JBSCW
JCJTX
JZLTJ
KDC
KOV
KOW
KPH
LAS
LLZTM
M1P
M2O
M4Y
MA-
N2Q
N9A
NB0
NDZJH
NPVJJ
NQJWS
NU0
O9-
O93
O9G
O9I
O9J
OAM
OVD
P19
P2P
P9S
PF0
PQQKQ
PROAC
PSQYO
PT4
PT5
Q2X
QOK
QOR
QOS
R89
R9I
RHV
RIG
RNI
ROL
RPX
RRX
RSV
RZK
S16
S1Z
S26
S27
S28
S37
S3B
SAP
SCLPG
SDE
SDH
SDM
SHX
SISQX
SJYHP
SMD
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZ9
SZN
T13
T16
TEORI
TSG
TSK
TSV
TT1
TUC
U2A
U9L
UG4
UKHRP
UNUBA
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W23
W48
WJK
WK8
X7M
YLTOR
Z45
Z7U
Z7W
Z7X
Z82
Z83
Z87
Z8O
Z8Q
Z8V
Z8W
Z91
ZGI
ZMTXR
ZOVNA
ZXP
~EX
~KM
AAEOY
AAKKN
AAYZH
ABAKF
ABEEZ
ACACY
ACULB
ACZOJ
AEFQL
AFBBN
AFGXO
AGQEE
AGRTI
AJOOF
ALIPV
C24
C6C
CGR
CUY
CVF
ECM
EIF
H13
NPM
AAYXX
CITATION
GROUPED_DOAJ
7TO
7XB
8FK
H94
K9.
MBDVC
PQEST
PQUKI
PRINS
Q9U
7X8
ID FETCH-LOGICAL-c324t-6f513f8cf4931c6a7f7cb00b77b251b3de7c6d2e3adc1d06a7efca65d1d1cdb93
IEDL.DBID AGYKE
ISSN 0171-5216
IngestDate Wed Dec 04 01:04:39 EST 2024
Tue Nov 19 06:18:49 EST 2024
Fri Dec 06 02:25:03 EST 2024
Tue Oct 15 23:49:23 EDT 2024
Sat Dec 16 12:01:08 EST 2023
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Endocrine therapy
Aromatase inhibitor
Early breast cancer
Exemestane
Language English
License http://www.springer.com/tdm
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c324t-6f513f8cf4931c6a7f7cb00b77b251b3de7c6d2e3adc1d06a7efca65d1d1cdb93
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-News-2
ObjectType-Feature-3
content type line 23
PMID 24271056
PQID 1473695347
PQPubID 47182
PageCount 10
ParticipantIDs proquest_miscellaneous_1490759729
proquest_journals_1473695347
crossref_primary_10_1007_s00432_013_1551_9
pubmed_primary_24271056
springer_journals_10_1007_s00432_013_1551_9
PublicationCentury 2000
PublicationDate 1-2014
2014-Jan
2014-1-00
20140101
PublicationDateYYYYMMDD 2014-01-01
PublicationDate_xml – year: 2014
  text: 1-2014
PublicationDecade 2010
PublicationPlace Berlin/Heidelberg
PublicationPlace_xml – name: Berlin/Heidelberg
– name: Germany
– name: Heidelberg
PublicationTitle Journal of cancer research and clinical oncology
PublicationTitleAbbrev J Cancer Res Clin Oncol
PublicationTitleAlternate J Cancer Res Clin Oncol
PublicationYear 2014
Publisher Springer Berlin Heidelberg
Springer Nature B.V
Publisher_xml – name: Springer Berlin Heidelberg
– name: Springer Nature B.V
References Thurlimann, Keshaviah, Coates (CR10) 2005; 353
Baum, Budzar, Cuzick (CR2) 2002; 359
Buzdar, Guastalla, Nabholtz, Cuzick (CR3) 2006; 107
Mouridsen, Giobbie-Hurder, Goldhirsch (CR8) 2009; 361
Aebi, Davidson, Gruber, Castiglione (CR1) 2010; 21
Coombes, Kilburn, Snowdon (CR4) 2007; 369
van de Velde, Rea, Seynaeve (CR11) 2011; 377
(CR5) 2005; 365
Goldhirsch, Ingle, Gelber (CR6) 2009; 20
Howell, Cuzick, Baum (CR7) 2005; 365
CR9
15894097 - Lancet. 2005 May 14-20;365(9472):1687-717
16804925 - Cancer. 2006 Aug 1;107(3):472-80
20555111 - Ann Oncol. 2010 May;21 Suppl 5:v9-14
15639680 - Lancet. 2005 Jan 1-7;365(9453):60-2
19535820 - Ann Oncol. 2009 Aug;20(8):1319-29
17307102 - Lancet. 2007 Feb 17;369(9561):559-70
12090977 - Lancet. 2002 Jun 22;359(9324):2131-9
16382061 - N Engl J Med. 2005 Dec 29;353(26):2747-57
21247627 - Lancet. 2011 Jan 22;377(9762):321-31
19692688 - N Engl J Med. 2009 Aug 20;361(8):766-76
M Baum (1551_CR2) 2002; 359
A Goldhirsch (1551_CR6) 2009; 20
B Thurlimann (1551_CR10) 2005; 353
Early breast Cancer Trialists’ Collaborative Group (EBCTCG) (1551_CR5) 2005; 365
H Mouridsen (1551_CR8) 2009; 361
AU Buzdar (1551_CR3) 2006; 107
1551_CR9
S Aebi (1551_CR1) 2010; 21
A Howell (1551_CR7) 2005; 365
CJH Velde van de (1551_CR11) 2011; 377
RC Coombes (1551_CR4) 2007; 369
References_xml – ident: CR9
– volume: 20
  start-page: 1319
  year: 2009
  end-page: 1329
  ident: CR6
  article-title: Thresholds for therapies: highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer 2009
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdp322
  contributor:
    fullname: Gelber
– volume: 365
  start-page: 60
  year: 2005
  end-page: 62
  ident: CR7
  article-title: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer
  publication-title: Lancet
  doi: 10.1016/S0140-6736(05)74803-0
  contributor:
    fullname: Baum
– volume: 377
  start-page: 321
  year: 2011
  end-page: 331
  ident: CR11
  article-title: Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(10)62312-4
  contributor:
    fullname: Seynaeve
– volume: 365
  start-page: 1687
  year: 2005
  end-page: 1717
  ident: CR5
  article-title: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
  publication-title: Lancet
  doi: 10.1016/S0140-6736(05)66544-0
– volume: 369
  start-page: 559
  year: 2007
  end-page: 570
  ident: CR4
  article-title: Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(07)60200-1
  contributor:
    fullname: Snowdon
– volume: 21
  start-page: v9
  issue: Suppl 5
  year: 2010
  end-page: v14
  ident: CR1
  article-title: Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdq159
  contributor:
    fullname: Castiglione
– volume: 361
  start-page: 766
  year: 2009
  end-page: 776
  ident: CR8
  article-title: Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa0810818
  contributor:
    fullname: Goldhirsch
– volume: 107
  start-page: 472
  year: 2006
  end-page: 480
  ident: CR3
  article-title: Impact of chemotherapy regimens prior to endocrine therapy: results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) trial
  publication-title: Cancer
  doi: 10.1002/cncr.22042
  contributor:
    fullname: Cuzick
– volume: 353
  start-page: 2747
  year: 2005
  end-page: 2757
  ident: CR10
  article-title: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa052258
  contributor:
    fullname: Coates
– volume: 359
  start-page: 2131
  year: 2002
  end-page: 2139
  ident: CR2
  article-title: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(02)09088-8
  contributor:
    fullname: Cuzick
– volume: 21
  start-page: v9
  issue: Suppl 5
  year: 2010
  ident: 1551_CR1
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdq159
  contributor:
    fullname: S Aebi
– volume: 359
  start-page: 2131
  year: 2002
  ident: 1551_CR2
  publication-title: Lancet
  doi: 10.1016/S0140-6736(02)09088-8
  contributor:
    fullname: M Baum
– volume: 107
  start-page: 472
  year: 2006
  ident: 1551_CR3
  publication-title: Cancer
  doi: 10.1002/cncr.22042
  contributor:
    fullname: AU Buzdar
– volume: 20
  start-page: 1319
  year: 2009
  ident: 1551_CR6
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdp322
  contributor:
    fullname: A Goldhirsch
– volume: 361
  start-page: 766
  year: 2009
  ident: 1551_CR8
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa0810818
  contributor:
    fullname: H Mouridsen
– volume: 365
  start-page: 1687
  year: 2005
  ident: 1551_CR5
  publication-title: Lancet
  doi: 10.1016/S0140-6736(05)66544-0
  contributor:
    fullname: Early breast Cancer Trialists’ Collaborative Group (EBCTCG)
– volume: 365
  start-page: 60
  year: 2005
  ident: 1551_CR7
  publication-title: Lancet
  doi: 10.1016/S0140-6736(05)74803-0
  contributor:
    fullname: A Howell
– ident: 1551_CR9
– volume: 353
  start-page: 2747
  year: 2005
  ident: 1551_CR10
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa052258
  contributor:
    fullname: B Thurlimann
– volume: 377
  start-page: 321
  year: 2011
  ident: 1551_CR11
  publication-title: Lancet
  doi: 10.1016/S0140-6736(10)62312-4
  contributor:
    fullname: CJH Velde van de
– volume: 369
  start-page: 559
  year: 2007
  ident: 1551_CR4
  publication-title: Lancet
  doi: 10.1016/S0140-6736(07)60200-1
  contributor:
    fullname: RC Coombes
SSID ssj0017572
Score 2.0773551
Snippet Purpose Prior chemotherapy may affect the efficacy of endocrine therapy. Methods The tamoxifen exemestane adjuvant multinational (TEAM) trial compared 5 years...
Prior chemotherapy may affect the efficacy of endocrine therapy. The tamoxifen exemestane adjuvant multinational (TEAM) trial compared 5 years of adjuvant...
Prior chemotherapy may affect the efficacy of endocrine therapy. The tamoxifen exemestane adjuvant multinational (TEAM) trial compared 5 years of adjuvant...
PURPOSEPrior chemotherapy may affect the efficacy of endocrine therapy. METHODSThe tamoxifen exemestane adjuvant multinational (TEAM) trial compared 5 years of...
SourceID proquest
crossref
pubmed
springer
SourceType Aggregation Database
Index Database
Publisher
StartPage 117
SubjectTerms Androstadienes - administration & dosage
Androstadienes - therapeutic use
Antineoplastic Agents, Hormonal - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Aromatase Inhibitors - therapeutic use
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - pathology
Cancer Research
Chemotherapy
Chemotherapy, Adjuvant
Clinical outcomes
Cohort Studies
Disease-Free Survival
Endocrine therapy
Female
Hematology
Humans
Internal Medicine
Medicine
Medicine & Public Health
Middle Aged
Neoplasm Grading
Neoplasm Staging
Oncology
Original Paper
Postmenopause
Retrospective Studies
Survival Rate
Tamoxifen - administration & dosage
SummonAdditionalLinks – databaseName: Public Health Database (Proquest)
  dbid: 8C1
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT8MwDI5gSIgL4s1goCBxAlUsS5ukJzShjQlpnDZpt6p5SRzWjj0O-_fYfQzQBNfWdVM7TT7bsU3IvVKAMpw3QVvHPABErLHNCxYE6GjJjFfWYaLw8F0MxuHbJJpUDrdFdayyXhOLhdrmBn3kTyyUXMQRD-Xz7DPArlEYXa1aaOySPYYbHWaKv2yOeMDOWDRvwpIwYHAxUUc122URUY6HEniAoCGIf-9LW2BzK1Ba7D_9I3JYAUfaLTV9THZcdkL2h1Vo_JQsyjrENPcUOORzCtqYVulVa4r9F6ZgsdI8o3CNOqwckZo1krsMvh6TAGlNjc7Zj4ym9BXX7YxiF915wRqfHfW6Q1p0-zgj435v9DIIqo4KgQHgtAyEjxj3yvgw5syIVHppQDVaSg04R3PrpBG243hqDbNtIAA1piKyzDJjQZvnpJHlmbskVHuAKsxxo1IfKtdWcRgpAXDDGKlCLZrkoZZnMisLZySbEsmF8BMQfoLCT-ImadUST6p_aJF8a7xJ7ja3YfZjSCPNXL5CGjDuwSbqAIuLUlObtwH4APgUwUgea9X9YP7XUK7-H8o1OQDIFJZOmBZpLOcrdwOwZKlvi7n3BQvc3Zo
  priority: 102
  providerName: ProQuest
Title Effect of prior chemotherapy regimens on the efficacy of endocrine therapy within a German cohort of the TEAM trial
URI https://link.springer.com/article/10.1007/s00432-013-1551-9
https://www.ncbi.nlm.nih.gov/pubmed/24271056
https://www.proquest.com/docview/1473695347
https://search.proquest.com/docview/1490759729
Volume 140
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LT9wwEB7xkKpeWuiDbgvIlTi1ymq9SWznuEULCLQIIVbanqL4JSGEg_ZxgF_PTF4CbXvgkkjOxHE8duazJ_MNwJFSiDKcN9FAZ3GEiFhTmhciBBhqyY1X1lGg8ORSnE2T81k624Bht3UR7vqtR7L6UHexbhV5XETJCMjKR9kmbKPpocm4PTr9ezHufAcyrVI2EREMLrO4aH2Z_6rktTVag5hr7tHK6px8rCMBFxVZIf1sctdfLXXfPK1TOb7hhXbgQwNC2ageNbuw4cIneDdp3OyfYVFzGrPSM6yznDPU7H0TqvXIKJfDPa5-WRkYljFHLBSFeSRxF2xpKKCQtdK00XsbWMFOyQYERhl551XVdO_NeDRhVeaQLzA9Gd8cn0VNdobIIAhbRsKnPPbK-CSLuRGF9NKgmrWUGjGTjq2TRtihiwtruB2gAA6JQqSWW24sjoyvsBXK4L4B0x5hD3exUYVPlBuoLEmVQOhijFSJFj341Wopf6hJOPKObrnqxhy7MaduzLMe7Ld6zJv5uMAFjoxFlsaJ7MHP7jLOJHKPFMGVK5LJED9luNrowV6t_-5pCGQQiqXYkt-tMl9U_r-mfH-T9A94j2gsqfd39mFrOV-5A0Q8S30Im3Im8aiO-WEz3PH8Z3x5dY2l0-HoGTbZ-kA
link.rule.ids 314,780,784,12056,12223,21388,27924,27925,31719,31720,33266,33267,33744,33745,41081,41523,42150,42592,43310,43579,43805,52111,52234,73745,74014,74302
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dT9swED9BkcZeJtgHK4PNSDwNRavrxHaeEKCybqMVQkXiLYq_pD2QsLY88N9zlzhlCG2viXNx7hz7d3f27wAOtUaU4YNNBiYXCSJiQ2VeiBBgaBS3QTtPB4UnUzm-Tn_eZDcx4LaI2yq7ObGZqF1tKUb-jadKyDwTqTq--5NQ1SjKrsYSGuuwQczpWQ82TkfTy6tVHkFlTfkmIoVBl4vLLq85aGlEBW1LEAnBhiR_vjK9gJsvUqXNCnS-BW8idGQnra23Yc1Xb-HVJCbH38GiZSJmdWAooZ4ztMdtPGD1wKgCwy36rKyuGF5jnrgjSvtAzX2F30_HAFnXmsKzvytWsu80c1eM6ujOG9H07Gx0MmFNvY_3cH0-mp2Nk1hTIbEInZaJDBkXQduQ5oJbWaqgLBrHKGUQ6RjhvLLSDb0oneVugA3QkKXMHHfcOrTnB-hVdeU_AjMBwQr3wuoypNoPdJ5mWiLgsFbp1Mg-fO30Wdy11BnFiiS5UX6Byi9I-UXeh71O40X8ixbFk837cLC6jeOfkhpl5et7aoPuPXpFQxSx01pq9TaEHwigMuzJUWe6v4T_qyu7_-_KF9gczyYXxcWP6a9P8BoBVNqGZPagt5zf-30EKUvzOY7ER8Md4ig
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT9wwEB7RRUK9oBbasgWKK_XUKiJeJ7ZzqqDdBUp3hSqQuEXxS-JAQneXA_-emcTZtkLlmkwm1owfnz3j-QA-aY0owwebpKYQCSJiQzQvVBBgZBS3QTtPF4WnM3l6lf24zq9j_tMiplX2c2I7UbvG0hn5Ic-UkEUuMnUYYlrExffJ17vfCTFIUaQ10mm8gHVcFdPRANaPx7OLX6uYgspbKicqEIPbLy77GGfalRQVlKIgEoIQSfHvKvUEej4Jm7ar0eQVbEYYyY46v7-GNV9vwcY0Bsq3YdFVJWZNYKihmTP0zW28bPXAiI3hFvevrKkZPmOe6khU9oHEfY22oCuBrJemo9qbmlXshGbxmhGn7rxVTd9ejo-mrOX-eANXk_Hlt9Mk8iskFmHUMpEh5yJoG7JCcCsrFZRFRxmlDKIeI5xXVrqRF5Wz3KUogE6tZO6449ahb9_CoG5qvwPMBAQu3Aurq5Bpn-oiy7VE8GGt0pmRQ_jc27O868polKuCya3xSzR-ScYviyHs9RYv44halH_8P4SPq9c4FijAUdW-uScZ3OrjDmmEKt51nlr9DaEIgqkcW_Kld91fyv_XlPfPN-UANrATlj_PZue78BKxVNadzuzBYDm_9_uIV5bmQ-yIj2O05lU
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+prior+chemotherapy+regimens+on+the+efficacy+of+endocrine+therapy+within+a+German+cohort+of+the+TEAM+trial&rft.jtitle=Journal+of+cancer+research+and+clinical+oncology&rft.au=Bossart%2C+Michaela&rft.au=Hadji%2C+Peyman&rft.au=Klar%2C+Maximilian&rft.au=Kieback%2C+Dirk+G&rft.date=2014-01-01&rft.eissn=1432-1335&rft.volume=140&rft.issue=1&rft.spage=117&rft.epage=126&rft_id=info:doi/10.1007%2Fs00432-013-1551-9&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0171-5216&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0171-5216&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0171-5216&client=summon